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BACKGROUND: Since the first facial allograft transplantation was reported in France in 2005, 18
cases have been performed in 4 countries and the rate is increasing.
METHODS: We have devised a survey to assess anesthesia-related management and rationale
of facial allograft transplantation. It was sent to the lead anesthesiologists of the first 14 face
transplants performed worldwide.
RESULTS: Responses were received corresponding to 13 face transplants. The median duration
of surgery and anesthesia was 19 hours (95% confidence interval 15–23 hours). The surgical
preparation and dissection of multiple small anatomical structures of the recipient was
time-consuming for 11 cases. Blood loss was considerable. All patients received packed red
blood cells (median 20 U, 95% confidence interval 5–28 U). A median of 13 L of crystalloid was
administered (95% confidence interval 10–18 L).
CONCLUSIONS: During facial allograft transplantation, the anesthesiologist must be prepared
for a long anesthetic with rapid blood loss after reperfusion of the graft. (Anesth Analg 2012;X:
●●●–●●●)
Facial allograft transplantation was first described in2005. Since then, 18 cases of partial or full-face trans-plantation have been performedworldwide. Only a few
centers have performed more than 1 face transplant and the
perioperative management is still evolving. Our survey sum-
marizes experiences with the first 14 face transplants.
METHODS
A questionnaire was designed to assess perioperative man-
agement focusing on items relevant to anesthesia care. The
IRB of Brigham and Women’s Hospital approved the study
and waived the requirement for written consent. Informed
consent was implied by voluntary completion of the survey.
Using media reports and medical publications, the lead
anesthesiologist corresponding to each known face trans-
plant that was performed before May 2011 was contacted
via phone or e-mail. All received an informational form
indicating approval of the IRB and an invitation to partici-
pate in the survey.
The questionnaire that was sent to the lead anesthesiologist
of each case required quantitative information such as “num-
ber of blood products transfused,” as well as open-ended
questions such as “What was your rationale for the choice of
vascular access?” Statistical analysis was performed on the
deidentified data using Stata 12 (StataCorp LP, College Sta-
tion, TX). A binomial method (“centile”) was used to deter-
mine conservative confidence intervals for the median values
presented.
RESULTS
Responses were obtained for 13 of 14 patients, correspond-
ing to 6 of 7 centers that had performed the procedure.
Table 1 lists a subset of the questions in the questionnaire
with results.
The median duration of surgery and anesthesia was 19
hours (95% confidence interval 15–23 hours). The surgical
preparation and dissection of multiple small anatomical
structures of the recipient was time-consuming for 11 cases.
Blood loss was considerable. All patients received packed
red blood cells (median 20 U, 95% confidence interval 5–28 U).
Other blood products administered included fresh frozen
plasma (FFP) and platelets. Confidence intervals are listed in
Table 1. A median of 13 L of crystalloid was administered
(95% confidence interval 10–18 L).
Table 1 also summarizes factors influencing assessment
of blood loss, use of catecholamines, airway management,
and vascular access as well as complications.
DISCUSSION
Face transplantation is a novel procedure that has been
performed for patients with debilitating facial injuries
caused by burns, blast injuries, and animal bites as well as
disfiguring diseases such as neurofibromatosis.
Two significant findings of this survey were the long
duration of surgery and anesthesia (median 19 hours) as
well as the high blood loss. A median of 20 U of packed red
blood cells, 13 U of FFP, 2 platelet units, and 13 L of
crystalloid was administered.
Most cases followed a similar course: The procedure
began with several surgical teams working in parallel while
performing microsurgical dissection of the recipient’s facial
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structures. Most patients had previously undergone mul-
tiple reconstructive procedures. Thus, the vascular struc-
tures and nerve supply can be severely distorted, requiring
time-consuming planning.
The next stage of surgery included reperfusion of the
donor facial graft. This marked the onset of blood loss in most
cases. Several factors may have contributed: after 1-sided
arterial and/or venous anastomosis of the graft, the contralat-
eral side was often allowed to bleed to allow for graft inflow
pressure equilibration, vasodilatation, and discharge of pre-
serving solutions as well as other compounds that may have
been used for allograft perfusion (tissue plasminogen activa-
tor, heparin, etc). In most cases, 4 vascular anastomoses were
completed, which is twice the number of the typical micro-
surgical reconstructive case, thereby accounting for the long
duration of this phase. Anesthesia teams reported that it was
difficult to recognize the extent of blood loss during this phase
in a timely manner. Factors such as bleeding into folded
drapes and poor visibility of the surgical site for the anesthesia
team were reported.
In the setting of blood loss and hypotension, vasopres-
sor medications were used. The need to restore perfusion
rapidly must be weighed against the risk of overhydration
and edema in the facial graft.1 Traditionally, the use of
vasopressor medications has been discouraged in the set-
ting of free flaps, even if used just to temporize. However,
this opinion is not supported by data from free flaps.1 More
efficient surgical suction into intraoperative cell salvage
machines (cell-savers) and alternative methods of collecting
shed blood such as into a sterile collecting bag should be
investigated, especially because exposure to allogenic
blood increases the risk of immunization2 and may com-
plicate the necessary, life-long, immunosuppression,3,4 in
addition to presenting an infection risk.5
Several teams were concerned about the risk of throm-
bosis in the facial graft and stated that they avoided use of
procoagulants such as FFP and platelets.
Other observations made in this study included relatively
uncomplicated airway management: 11 of 13 patients had a
tracheostomy by the end of the case. Seven patients had a
preexisting tracheostomy. Two of these required surgical
enlargement under sedation before cannulation. Only 1 pa-
tient required fiberoptic orotracheal intubation for a known
difficult airway. Many centers reported that they avoided
circumferential neck ties to fasten the airway device because
of a concern for neck swelling and subsequent venous outflow
obstruction of the facial graft. Because the patients were often
turned 180° away from the anesthesiologist for most of these
long cases, the anesthesiologist could not easily monitor and
adjust the tension of the tie to avoid constriction as tissue
edema developed. Most often, an armored endotracheal tube
was inserted into the tracheostomy site, bent caudally toward
the anesthesiologist, and sutured to the chest wall.
Vascular access was most often achieved via femoral
venous and arterial catheterization as indicated in Table 1.
Avoiding internal jugular or subclavian veins because of
Table 1. Selected Elements of Survey and Responses Received for 13 Cases of Face Transplantation
Question in survey Evaluation of responses with number of cases
Duration of anesthesia (reported as
median with 95% confidence interval)
● 19 h (15–23)a
Resuscitation required (reported as
median with 95% confidence interval)
● pRBCsa: 20 (5–28)
● Fresh frozen plasma: 13 (0–23)
● Plateletsb: 2 (0–5)
● Crystalloid: 13 (10–18) (1 response missing)
Factors influencing blood loss and reason
for difficulty assessing blood loss
● Bleeding from arterial and venous anastomoses not controlled optimally after reperfusion, 10
● Poor visualization of surgical site by anesthesia team, 10
● Irregular use of surgical suction, loss of blood into drapes, and difficult to estimate, 8
● Bleeding excessive from osteotomy sites, 2
Were catecholamines used during surgery? ● Use of any catecholamine including intermittent boluses, 7
● Continuous infusion of a catecholamine over 2 h, 6
Describe airway management ● Primary intubation of existing tracheostoma using armored ETT, 7 cases
● Surgical enlargement of existing tracheostoma necessary to place ETT, 2 cases
● Primary orotracheal intubation, 6 cases
● Known difficult intubation, 1 case
● Surgery performed entirely without requiring tracheostomy, 2 cases
Location of vascular access ● Femoral venous multilumen catheter, 11 (of these, 4 were with large-bore introducer sheaths)
● Subclavian multilumen catheters, 2
● Radial arterial line placed, 6
● Femoral arterial line placed, 8
State rationale for preference of femoral
location for venous access
● 9 cited concerns about thrombosis in the internal jugular or subclavian vein with extension
into the superior vena cava and obstruction of venous outflow from the face
● 5 cited risk of pneumothorax in a long anesthetic with mechanical ventilation
Complications ● Thrombosis in facial veins,c 2
● Facial hematomas,c 2
● Pneumonia, radiographically consistent with aspiration, 2
● Reversible renal dysfunction,d 3
ETT  endotracheal tube; pRBCs  packed red blood cells.
a The rank correlation (Spearman correlation) between duration of anesthesia and number of units of pRBCs transfused was low and not significant (P  0.37).
b We refer to 1 U of platelets as either collected from 6 whole blood donations or plasmapheresed from 1 donor and containing approximately 3–4  1011
platelets.
c Required operative revision.
d Defined as creatinine 1.3 mg/dL.
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concern for subsequent thrombosis and subsequent ob-
struction of venous outflow from the facial graft was cited
by several groups. However, few data are available to
assess the risk of short-term cannulation in otherwise
healthy patients. Little is known about the relative infec-
tious risk of femoral access in these highly immunosup-
pressed patients.
During facial allograft transplantation, the anesthesiologist
must be prepared for a long anesthetic with rapid blood loss
after reperfusion of the graft.
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